Bioneex and ALSA Ventures Partner to Provide Biotech Firms a New Way to Drug Candidate Out-Licensing and Acquiring Investment

Tue Mar 22 2022 12:28:00 GMT+0000 (Coordinated Universal Time)

Biotech, biopharma companies, and research institutions by listing their drug candidates on Bioneex connect directly with potential licensing and co-development partners as well as investors

NEW YORK, March 22, 2022 /PRNewswire-PRWeb/ --BioNeex (,  the biopharma industry’s first research and development (R&D) open exchange platform, announced today it is partnering with ALSA Ventures to help preclinical and early clinical-stage biotech companies and research institutions identify business development opportunities for their drug development pipeline. The partnership provides a new way for development-stage biotech companies to out-license drug candidates and acquire investments from venture capital firms, using a two-sided marketplace that connects both parties directly.

“Bioneex is an online marketplace where biotech, biopharma companies and research institutions can list their drug candidates available for licensing or co-development partnerships,” said Dr. Smbat Rafayelyan, Founder & CEO of Bioneex. “The Bioneex exchange allows biopharma, biotech companies, research institutions and venture capital firms to meet and create R&D licensing, co-development partnerships, and investment opportunities.”

Bioneex offers the most complete, accurate and up-to-date data in the biopharma industry, posted directly by drug candidate developers. Bioneex and London-based venture capital firm ALSA are improving how venture capital firms identify biopharma licensing and investment opportunities, backed by proprietary real-time data on industry trends and analysis. Ten of the twenty largest biopharmaceutical companies already use the Bioneex platform to strengthen their R&D pipelines. The exchange is highly focused on novel drug candidates – new molecular entities (NMEs) that are first-in-class, best-in-class.

“We encourage all of our ALSA portfolio companies, as well as other development-stage biotech firms looking for out-licensing or co-development partnerships or investments, to list their drug candidates on the Bioneex platform,” said Alek Safarian, CEO of ALSA Ventures. “This is a bold new step in the future of biopharma licensing and investment in the U.S. and around the world. With better, more in-depth data available to investment partners, the industry is poised for even stronger growth.”

“Bioneex is helping preclinical and early clinical-stage biotech companies gain vital exposure for drug candidate out-licensing and acquiring investment, increasing the likelihood that innovative drug candidates will ultimately reach the late-stage clinical development and go on to become novel medicines,” said Dr. Rafayelyan. “The Bioneex exchange is an innovative new way of deal sourcing for venture capital firms to identify biopharma in-licensing and investment opportunities, and this is what our partnership with ALSA Ventures proves.”

About Bioneex
Bioneex is the first R&D open exchange platform in the biopharma industry, facilitating licensing and co-development partnerships for preclinical and clinical-stage drug candidates between biotech, biopharma companies and research institutions. Data posted on the drug candidate marketplace is listed by biotech, biopharma companies, and research institutions, enabling potential licensing and co-development partners as well as investors to contact them directly with one click. For more information, please visit:

About ALSA Ventures
ALSA Ventures is a life science venture capital investor, focused on early-stage novel therapeutics. With a strong operations background in drug development, the team seeks to bring together outstanding entrepreneurs and world class academic researchers to help bring promising new treatments to market. ALSA invests across a wide spectrum of therapeutic areas, targeting high unmet need with impactful outcomes for patients and society at large. For more information, please visit:

Sourc:  PRWeb

Schedule a call or send us a message
Schedule Call
Contact us